hVIVO PLC (LON:HVO)

hVIVO PLC (LON:HVO)


Share Price
20.00 p
Change
-0.25 (-1.23 %)
Market Cap
£16.60 m
Proactive Investors - Run By Investors For Investors

hVIVO PLC

Established in 1989 as a spin out from Queen Mary University, London, hVIVO is a trusted partner and industry-leading clinical development services business pioneering human disease models based upon viral challenge. Using human challenge studies to establish early proof-of-concept, hVIVO’s clinical trial platform can accelerate drug and vaccine development in respiratory and infectious...

EPIC: HVO
Market: LSE:HVO
52-week High/Low: 74.400p / 18.000p
Sector: Pharma & Biotech
Market Cap: £16.60 m
Website: hvivo.com
col 3
col 4
col 5
col 6

Big Picture – A Deep Dive Examination of hVIVO PLC


hVIVO PLC Snapshot

Vision / Strategy

Our Vision and Values

To become the partner of choice for companies developing products in airways disease.

 

Our Mission

Overcome unmet medical need barriers by providing human models of disease which bridge the translation gap from animal to man, and which can illuminate the molecular and cellular causes of disease.

 

hVIVO: Better treatments, faster.

The demand for new treatments in the drive towards a healthier world is a pressing one. There is a real need to better understand the true causes of debilitating and life threatening conditions and identify the best way to alleviate or cure them.

 

Our Values: One team, Growth, Integrity, Innovation

One team:

We work as one high performing team, each playing to our best, committed to delivering shared goals with passion, energy and enthusiasm. Succeeding together is as important as succeeding individually. We celebrate success together.

Growth:

We are committed to growing and developing our employees, professionally and personally, through our unique experiences in a scientifically, intellectually, pioneering environment. Our vision is inspiring, opening up unexplored opportunities and the ability to achieve.

Integrity:

We take personal ownership for our actions and always act in ways that build trust and respect with the people around us. We believe in clear, open and honest communication.

Innovation:

We are pioneering in our approach, working with level headedness and listening to others’ ideas. We are courageous in embracing new challenges and in our determination to do things differently and better. Our agility allows us to define and redefine our markets.

Laboratory Services

The Challenge

United Kingdom.

Dr Trevor Phillips
Executive Chairman

Appointment to the Board:

Dr Trevor Phillips was appointed to the hVIVO Board as a Non-Executive Director in June 2017 and subsequently Executive Chairman in November 2017.

Experience and expertise

Trevor has over 30 years of experience within the pharmaceutical industry, including extensive international drug development and corporate development responsibilities. He was previously Chief Operations Officer and President of US Operations, as well as a member of the Board, at Vectura Group plc, a FTSE 250 company listed on the London Stock Exchange focussed on airways diseases. Subsequent to joining Vectura in
2010, Trevor played an integral leadership role in the company’s successful development, including the acquisition of Activaero GmbH in 2014 and the merger with Skyepharma plc in 2016. Prior to joining Vectura, Trevor held the roles of Chief Executive Officer and Chief Operating Officer at Critical Therapeutics, Inc. (now Chiesi USA, Inc.), a US listed specialty pharmaceutical company, where he was involved in setting up commercial partnerships, product in-licensing and out-licensing, managing drug development, commercial product manufacturing and M&A activity. He led the merger of Critical Therapeutics with Cornerstone BioPharma Holdings. He has also held senior management positions at Sepracor, Inc. (now Sunovion Pharmaceuticals, Inc.), Accenture plc and GlaxoWellcome plc (now GlaxoSmithKline plc). Trevor trained as a microbiologist at University of Reading, obtaining a PhD in microbial biochemistry from the University of Wales in 1986.
He was awarded an MBA from Henley Management College in 1997.

Current external appointments

Trevor is currently Non-Executive Director at Morvus Technology Ltd and Non-Executive Director at NEPeSMO Ltd.

Tim Sharpington
Chief Operating Officer

Tim brings to hVIVO more than 25 years’ experience in the life sciences sector with various pharmaceutical, biotechnology and pharmaceutical service companies in Europe and the US. He has broad experience in drug development, product licensing, mergers, acquisitions and fundraisings. Tim’s previous positions include chief executive officer at Phytopharm plc and Serentis Limited and executive vice president at Vectura plc, a UK company also focussed on airways disease. Tim is a non-executive director and senior independent director of Ixico plc.

Shelley Fraser
Finance Director and Company Secretary

 

Shelley joined hVIVO as Vice President, Finance and was appointed Finance Director and Company Secretary in January 2019. Shelley has over 18 years’ experience in the pharmaceutical, biotech and life sciences industry, operating in service and product offering environments. A chartered accountant, she has worked in Asia Pacific and Europe, reporting to US blue chip companies, Merck and Thermo Fisher Scientific. Shelley has spent more than 15 years as Finance Director, with broader responsibilities covering facilities, supply chain, IT and HR.

Reid Tripp
Executive Vice President, Business Development and Marketing

 

Before joining hVIVO, Reid held senior management business development and marketing positions with various large, mid-sized and small global clinical research organisations where he successfully built and managed sales, marketing, proposals and contracts teams, delivered hundreds of millions in contractual relationships and overall, enhanced customer satisfaction. Reid has also served in a senior management role at a start-up biotechnology company and has held various management positions for a large pharmaceutical company.

Fleur Wood
Executive Vice President, Investor Relations and Communications

 

Fleur brings over 20 years’ experience in investor relations, communications and capital markets gained primarily within the UK investment banking industry and the pharmaceuticals sector. During her career, she has brought strategic IR skills to both M&A situations and to companies undergoing growth and change. Fleur’s previous role was at Vectura Group plc, a FTSE 250 company listed on the London Stock Exchange focussed on airways diseases, where she held positions as director of communications and director of investor relations. She played an integral role in the acquisition of Activaero GmbH in 2014 and the merger with Skyepharma plc in 2016.

Number of Securities in Issue

The total number of Ordinary Shares of 5p each in the capital of the Company in issue is 82,957,337 shares, with each share carrying the right to one vote (as at 1st April 2019).

Directors and their Interests

The Directors and their interests in the ordinary share capital of the Company are as follows:

Significant Shareholders as at 1 April 2019

The Company has been notified of or is aware of the following significant shareholders:

There are no restrictions on the transfer or sale of the Company’s shares.

The percentage of the Company’s issued share capital that is not in public hands is 70.7%.

 

Main London office and registered business address:

hVIVO Services Limited
Queen Mary BioEnterprises (QMB) Innovation Centre
42 New Road
London E1 2AX
United Kingdom

Main Switchboard:

+44 (0) 20 7756 1300

Investor Contacts

For all shareholder enquiries please contact:

Fleur Wood, EVP, Investor Relations & Communications

Tel: +44 (0)20 3021 0280

Main London office and registered business address:

hVIVO Services Limited
Queen Mary BioEnterprises (QMB) Innovation Centre
42 New Road
London E1 2AX
United Kingdom

Main Switchboard:

+44 (0) 20 7756 1300

Investor Contacts

For all shareholder enquiries please contact:

Fleur Wood, EVP, Investor Relations & Communications

Tel: +44 (0)20 3021 0280

Auditor

Ernst & Young LLP, Apex Plaza, Forbury Road, Reading, Berkshire, RG1 1YE

Nominated adviser and broker

Numis Securities Limited, The London Stock Exchange Building, 10 Paternoster Square, London, EC4M 7LT

Solicitors

Pinsent Masons LLP, 30 Crown Place, London, EC2A 4ES

Registrars

Equiniti, Aspect House, Spencer Road, Lancing, BN99 6DA

Registered office

Queen Mary BioEnterprises Innovation Centre, 42 New Road, London, E1 2AX

Registered in England and Wales, Registered number 08008725

 

Columns Including HVO

VIEW ALL

Market Reports Including HVO

VIEW ALL
Video RSS

Videos

VIEW ALL VIDEOS

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use